research 605 Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis
This study examined the safety and efficacy of dupilumab in adolescents with moderate-to-severe atopic dermatitis, finding that it was well tolerated and significantly improved symptoms over 52 weeks, with its safety profile similar to that in adults.
